Related Experiment Video

Updated: Jun 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

LKB1 and Src: antagonistic regulators of tumor growth and metastasis

Jill Slack-Davis1, John O Dasilva, Sarah J Parsons

  • 1Department of Microbiology and Cancer Center, University of Virginia, Charlottesville, VA 22908, USA.

Cancer Cell
|June 15, 2010
PubMed

Insights

Loss of the LKB1 tumor suppressor activates Src and FAK signaling in lung cancer. This discovery opens avenues for novel combinatorial therapies targeting these specific pathways for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Lung cancer is a leading cause of cancer-related mortality worldwide.
  • The LKB1 (Liver kinase B1) tumor suppressor plays a critical role in cellular regulation and is frequently inactivated in lung cancers.
  • Aberrant signaling pathways contribute significantly to lung cancer progression and therapeutic resistance.

Discussion:

  • Carretero and colleagues identify the activation of Src and FAK signaling pathways as a key consequence of LKB1 deletion in lung cancer.
  • This activation suggests a direct link between LKB1 loss and specific oncogenic signaling cascades.
  • Understanding these downstream effects of LKB1 inactivation is crucial for developing targeted treatment strategies.

Key Insights:

  • Src and FAK signaling pathways are significantly activated in lung cancers characterized by LKB1 deletion.
  • LKB1 acts as a crucial regulator, and its loss unleashes potent pro-tumorigenic signaling.
  • This provides a molecular rationale for targeting Src and FAK in LKB1-deficient lung tumors.

Outlook:

  • The findings pave the way for developing novel combinatorial therapies specifically for LKB1-mutated lung cancers.
  • Targeting the activated Src and FAK pathways could offer a new therapeutic window.
  • Further research is warranted to translate these findings into effective clinical interventions for lung cancer patients.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.